Lessons Learned from Pharmaceutical Nanomaterials - Safety of Nanomaterials along Their Lifecycle - page 133

Rathore, A. S (2009) Roadmap for implementation of quality by design (QbD) for biotechnol-
ogy products. Trends Biotechnol 27 (9):546-553.
Ringel, I. and S. B. Horwitz (1991) Studies with RP 56976 (taxotere): A semisynthetic ana-
logue of taxol. J Natl Cancer Inst 83 (4):288-291.
Rohwedel, J., K. Guan, C. Hegert, and A. M. Wobus (2001) Embryonic stem cells as an in
vitro model for mutagenicity, cytotoxicity and embryotoxicity studies: Present state and
future prospects. Toxicol in vitro 15 (6):741-753.
Rowinsky, E. K., L. A. Cazenave, and R. C. Donehower (1990) Taxol: A novel investigational
antimicrotubule agent. J Natl Cancer Inst 82 (15):1247-1259.
Schiff, P. B. and S. B. Horwitz (1980) Taxol stabilizes microtubules in mouse fibroblast cells.
Proc Natl Acad Sci U S A 77 (3):1561-1565.
Schmidt, C., C. Lautenschlaeger, E. M. Collnot, M. Schumann, C. Bojarski, J. D. Schulzke,
C. M. Lehr, and A. Stallmach (2013) Nano- and microscaled particles for drug targeting
to inflamed intestinal mucosa: A first in vivo study in human patients. J Control Release
165 (2):139-145.
Scholz, G., I. Pohl, E. Genschow, M. Klemm, and H. Spielmann (1999) Embryotoxicity
screening using embryonic stem cells in vitro: Correlation to in vivo teratogenicity.
Cells Tissues Organs 165 (3-4):203-211.
Shao, L., M. J. Pollard, P. R. Griffiths, D. T. Westermann, and D. L. Bjorneberg (2007)
Rejection criteria for open-path Fourier transform infrared spectrometry during con-
tinuous atmospheric monitoring. Vib Spectrosc 43 (1):78-85.
Skyler, J. S., L. Jovanovic, S. Klioze, J. Reis, and W. Duggan (2007) Two-year safety and effi-
cacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes
Care 30 (3):579-585.
Slutter, B., L. Plapied, V. Fievez, M. A. Sande, A. des Rieux, Y. J. Schneider, E. Van Riet, W.
Jiskoot, and V. Preat (2009) Mechanistic study of the adjuvant effect of biodegradable
nanoparticles in mucosal vaccination. J Control Release 138 (2):113-121.
Sparreboom, A., L. Van Zuylen, E. Brouwer, W. J. Loos, P. De Bruijn, H. Gelderblom, M.
Pillay, K. Nooter, G. Stoter, and J. Verweij (1999) Cremophor EL-mediated alteration of
paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer
Res 59 (7):1454-1457.
Subramaniam, V., H. Li, M. Wong, R. Kitching, L. Attisano, J. Wrana, J. Zubovits, A. M.
Burger, and A. Seth (2003) The RING-H2 protein RNF11 is overexpressed in breast
cancer and is a target of Smurf2 E3 ligase. Br J Cancer 89 (8):1538-1544.
Todoroff, J. and R. Vanbever (2011) Fate of nanomedicines in the lungs. Curr Opin Colloid
In 16 (3):246-254.
TAXOL (paclitaxel) Injection (Patient Information Included) (2011) Available from package-
inserts.bms.com/pi/pi_taxol.pdf (accessed last on 10.07.14).
Tosi, G., L. Costantino, B. Ruozi, F. Forni, and M. A. Vandelli (2008) Polymeric nanoparticles
for the drug delivery to the central nervous system. Expert Opin Drug Deliv 5 (2):155-174.
Tsapis, N., D. Bennett, B. Jackson, D. A. Weitz, and D. A. Edwards (2002) Trojan particles:
Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A 99
(19):12001-12005.
Vaage, J., E. Barbera-Guillem, R. Abra, A. Huang, and P. Working (1994) Tissue distribution
and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on
human prostate carcinoma xenografts. Cancer 73 (5):1478-1484.
Veronese, F. M. and G. Pasut (2005) PEGylation, successful approach to drug delivery. Drug
Discov. Today 10 (21):1451-1458.
Wagner, V., B. Hüsing, S. Gaisser, and A. Bock (2008) Nanomedicine: Drivers for develop-
ment and possible impacts. JRC-IPTS . Luxembourg: Spain.
Wahl, B., N. Daum, H. L. Ohrem, and C. M. Lehr (2008) Novel luminescence assay offers new
possibilities for the risk assessment of silica nanoparticles. Nanotoxicology 2 (4):243-251.